Corporate green goals driving PAT adoption

GlaxoSmithKline plant managers are jumping on the process analytical technology train. But process control is not the sole driver. GSK, like other drugmakers, is seeing PAT provide a boost for its sustainability efforts.

The trend is currently most apparent in its pilot plants, according to PharmaManufacturing.com. Managers trying to reduce cycle times and realize energy and cost savings are considering and adopting the technology.

In a recent survey conducted by the online magazine, ten percent of respondents say that sustainability has become a key driver of their PAT efforts. About half of the 50 respondents say they see PAT as a means toward sustainability and green practices.

PAT has "moved up in status, and moved upstream in the development cycle," according to the article. "Manufacturers are beginning to equate PAT with reducing the environmental impact of processes."

- here's the article

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.